Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationCost of RevenueEBIATLoans and Notes ReceivablesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Receivables - NetReceivables - Other
Ratios

Lifecore Biomedical, Inc. \De\ (LFCR) Accumulated Depreciation & Amortization (2016 - 2025)

Lifecore Biomedical, Inc. \De\ (LFCR) has 15 years of Accumulated Depreciation & Amortization data on record, last reported at $8.0 million in Q2 2025.

  • For Q2 2025, Accumulated Depreciation & Amortization rose 0.92% year-over-year to $8.0 million; the TTM value through May 2025 reached $8.0 million, up 0.92%, while the annual FY2025 figure was $8.0 million, 0.92% up from the prior year.
  • Accumulated Depreciation & Amortization reached $8.0 million in Q2 2025 per LFCR's latest filing, up from $6.1 million in the prior quarter.
  • Across five years, Accumulated Depreciation & Amortization topped out at $19.9 million in Q2 2021 and bottomed at $2.0 million in Q3 2024.
  • Average Accumulated Depreciation & Amortization over 5 years is $8.7 million, with a median of $7.6 million recorded in 2022.
  • Peak YoY movement for Accumulated Depreciation & Amortization: rose 11.89% in 2021, then crashed 50.21% in 2023.
  • A 5-year view of Accumulated Depreciation & Amortization shows it stood at $11.0 million in 2021, then crashed by 33.65% to $7.3 million in 2022, then plummeted by 46.07% to $3.9 million in 2023, then grew by 2.62% to $4.0 million in 2024, then skyrocketed by 98.84% to $8.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Accumulated Depreciation & Amortization were $8.0 million in Q2 2025, $6.1 million in Q1 2025, and $4.0 million in Q4 2024.